Recent findings published in Scientific Reports highlight a promising target for ovarian cancer drug development, emphasizing the importance of Claudin-4 in tumor progression and resistance. The study ...

) has been revised to $245.38 / share. This is an increase of 30.33% from the prior estimate of $188.28 dated September 27, 2025. The price target is an average of many targets provided by analysts.

KeyBanc raised the firm’s price target on Advanced Energy (AEIS) to $180 from $160 and keeps an Overweight rating on the shares. The firm cites increasing sentiment on Advanced Energy’s competitive ...

The average one-year price target for Advanced Energy Industries (NasdaqGS:AEIS) has been revised to $173.91 / share. This is an increase of 13.14% from the prior estimate of $153.71 dated September ...

Advanced Micro Devices (NASDAQ:AMD – Free Report) had its price objective lowered by HSBC from $200.00 to $185.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The ...